The End of 280E: How Schedule III Tax Relief Is Reshaping Cannabis

The Tax Code That Nearly Killed an Industry

For four decades, Section 280E of the Internal Revenue Code has been the most punishing line item on every cannabis company's balance sheet. Originally enacted in 1982 after a drug dealer successfully deducted business expenses on his tax return, the provision was never designed with legal state-licensed cannabis operators in mind. But its effect has been devastating: by preventing businesses that traffic in Schedule I or Schedule II controlled substances from deducting ordinary business expenses, 280E has imposed effective federal tax rates that routinely exceed 70 percent — and in some documented cases have surpassed 90 percent.

Think about what that means in practical terms. A cannabis dispensary generating $5 million in revenue with $4 million in operating expenses — wages, rent, utilities, insurance, marketing — couldn't deduct most of those costs. The IRS calculated taxable income as if those expenses didn't exist, producing a tax bill that often exceeded the company's actual profit. Businesses that would be solidly profitable in any other industry operated at razor-thin margins or outright losses, solely because of a tax provision written during the Reagan administration's war on drugs.

With the DOJ's April 2026 order moving medical marijuana to Schedule III, the 280E stranglehold is finally loosening — at least for qualifying operators. The implications are seismic, and they're only beginning to ripple through the industry.

What Changed on April 22

When the Department of Justice issued its final order placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, it didn't just change how the government classifies marijuana. It fundamentally altered the tax treatment of an entire industry overnight.

Section 280E applies exclusively to businesses trafficking in Schedule I or Schedule II controlled substances. Schedule III substances are exempt. That single reclassification means that medical cannabis operators with qualifying state licenses can now deduct all the ordinary business expenses that every other American business takes for granted: employee compensation, facility costs, professional services, marketing expenditures, depreciation, and research investments.

The Treasury Department and IRS moved quickly to acknowledge the shift, announcing on April 23 that formal guidance was forthcoming, including a transition rule that applies the rescheduling to the full taxable year containing the effective date. For operators on a calendar tax year, that means 280E relief applies retroactively to January 1, 2026 — a meaningful windfall for businesses already several months into their fiscal year.

The Scale of the Financial Impact

The numbers are staggering. Industry analysts estimate that eliminating 280E for the medical cannabis sector could save operators hundreds of millions of dollars annually in aggregate. For individual companies, the swing from 280E to standard tax treatment can transform a struggling operation into a solidly profitable one without changing a single aspect of how the business actually operates.

Consider a mid-size medical cannabis operation with $20 million in revenue and $15 million in operating expenses. Under 280E, much of that $15 million was non-deductible, potentially yielding a federal tax liability that consumed most or all of the company's economic profit. Under standard Schedule III treatment, the business can deduct those expenses normally, reducing taxable income to $5 million and producing a federal tax bill of roughly $1.05 million at the 21 percent corporate rate. The difference between the two scenarios can easily run into the millions — for a single company in a single year.

At the industry level, the major publicly traded multi-state operators stand to see the most dramatic improvements. Companies like Trulieve, which has already filed for DEA Schedule III registration, could see their medical-side margins improve by 20 to 30 percentage points essentially overnight. For companies that have been burning through cash to sustain operations under 280E's weight, the tax relief represents not just improved profitability but genuine long-term viability.

The Retroactivity Question

Perhaps the most consequential unresolved question is whether 280E relief will be applied retroactively to prior tax years. Every medical cannabis operator that filed federal returns under 280E from 2014 onward — the standard period for amended return filing — could theoretically submit amended returns claiming deductions that were previously disallowed.

If the IRS permits retroactive claims, the refund pool could be enormous. Cannabis businesses that paid millions in excess taxes over the past decade would have strong incentive to pursue amended filings, potentially recovering a significant portion of those overpayments.

The legal basis for retroactive claims is still being debated. Some tax attorneys argue that the rescheduling creates an immediate basis for amending prior returns, while others contend that the IRS will issue specific guidance limiting retroactivity. The answer could take months to materialize, but operators are being advised to preserve all records and document their expense histories in preparation for either outcome.

The Adult-Use Gap

Here's where the celebration gets complicated. The April 2026 rescheduling order applies specifically to medical marijuana — products with FDA approval or those operating under qualifying state medical licenses. Recreational cannabis remains classified as Schedule I, which means adult-use operators are still fully subject to 280E.

This creates a stark divide within the industry. In states like Florida, where only medical sales are currently permitted, every operator benefits from the rescheduling. But in states with both medical and adult-use programs — Colorado, California, Michigan, Illinois — companies must now segregate their medical and recreational operations for tax purposes. Medical-side revenue qualifies for standard deductions; adult-use revenue does not.

The segregation requirement introduces accounting complexity and operational headaches. Companies with integrated operations — a single facility serving both medical and recreational customers, for example — face decisions about how to allocate shared costs between the two revenue streams. The IRS hasn't yet issued detailed guidance on allocation methodologies, leaving operators and their tax advisors to navigate uncertain terrain.

The June 29 DEA hearing, which will consider whether to extend Schedule III status to all marijuana including adult-use products, looms as the next critical milestone. If the hearing leads to comprehensive rescheduling, the 280E question resolves cleanly. If not, the industry could face an extended period of split tax treatment that advantages medical operators and penalizes those focused on recreational markets.

How the Industry Is Responding

The financial implications of 280E relief are already showing up in corporate strategy. Several major MSOs have announced plans to increase capital investment, citing the improved cash flow that Schedule III status provides. Others are revisiting M&A plans that were shelved when 280E made acquisition targets look unprofitable on paper.

Banking relationships are also shifting. Financial institutions that have been reluctant to serve cannabis businesses — or that charged premium fees to offset perceived legal risk — are reconsidering their positions now that Schedule III operators fall into a more conventional regulatory category. More accessible and affordable banking could reduce another significant cost burden that has weighed on the industry.

For smaller operators, the impact may be even more dramatic. Small and mid-size cannabis businesses have been disproportionately harmed by 280E because they lack the scale to absorb excessive tax burdens. Relief could be the difference between survival and closure for businesses that have been operating on the edge for years.

What Comes Next

The end of 280E — at least for medical cannabis — marks a turning point in the financial maturation of the American cannabis industry. For the first time, a significant portion of the legal market will operate under the same basic tax framework as any other business. That's not a small thing. It's the removal of the single largest structural disadvantage that legal cannabis operators have faced since the first state programs launched.

But the story isn't finished. Adult-use operators remain under 280E's shadow, the retroactivity question is unresolved, and the June hearing could change everything again. What's certain is that the cannabis industry's tax landscape in December 2026 will look nothing like it did in January. For operators who have spent years fighting an impossible tax code, that's progress worth recognizing.

For readers ready to take the next step, Budpedia maintains the most comprehensive cannabis dispensary directory in the United States — license-verified, with hours, menus, and real reviews for every listing across 48 legal states.